month history of progressive spastic paraparesis associated with optic neuropathy and a T10 sensory level. Magnetic resonance imaging demonstrated multifocal, contrast-enhancing lesions in the spinal cord. The patient was diagnosed as having CNS-SS because of the presence of sicca symptoms, abnormal serological test results, and salivary gland biopsy results, which fulfilled San Diego criteria for "definite" Sjö gren syndrome. She responded to treatment with a combination of prednisone and cyclophosphamide.
Conclusions: Diagnosis of primary CNS-SS requires a high index of suspicion and specialized clinical testing. Treatment with pulse doses of corticosteroids alone may be suboptimal, but results of treatment with a combination of corticosteroids and either cyclophosphamide or chlorambucil have been encouraging.
Arch Neurol. 2001; 58:815-819 S JÖ GREN SYNDROME (SS) is a chronic autoimmune disorder affecting the exocrine glands that is manifested clinically by keratoconjunctivitis sicca, xerostomia, and multiple abnormalities of cellular and humoral immunity. Systemic disease may also occur, resulting in extraglandular complications, including involvement of the central and peripheral nervous systems. 1, 2 It is usually considered a disease of older persons, but also can affect younger individuals. Primary SS presents with sicca complex alone, whereas secondary forms occur in conjunction with another connective tissue disorder, most commonly rheumatoid arthritis. 1 Peak prevalence is at 40 to 50 years of age, with a female-male ratio of 9:1. 2 The use of 2 separately devised classification schema, the San Diego 3 and European 4 criteria ( Clinical diagnosis of SS requires a high index of suspicion, especially when the first manifestations are neurologic. Peripheral neuropathy is well recognized, occurring in about 10% to 35% of patients with primary SS. 2 Central nervous system (CNS) involvement in primary SS (CNS-SS) is less common, and its manifestations may be localized (optic neuropathy, hemiparesis, transverse myelitis, and dystonia) or diffuse (encephalopathy and dementia). A combination of lesions and the presence of relapses and remissions often suggests multiple sclerosis. 1, 5 We report herein 17 cases 6-17 ( to a combination of prednisone and cyclophosphamide, as previously reported. 10 
REPORT OF A CASE
A 63-year-old Hispanic woman presented with paraplegia, preceded by asymmetric sensory symptoms in her legs for 10 months. Urinary frequency and urgency, occasional dysuria, and urinary incontinence developed in the few weeks before admission.
Four months earlier, she had undergone an extensive evaluation. Relevant findings on neurologic examination included spastic paraparesis, worse on the left side and with lower limb hyperreflexia; a sensory level was not present, but hypoesthesia to pinprick was noted in her left buttock and posterior thigh. Plantar responses were flexor. Magnetic resonance imaging (MRI) demonstrated abnormal focal signal intensities on T2-weighted images at the C5-6 and T8-9 levels and on the conus medullaris and cauda equina (Figure, A) . These same regions were enhanced by the administration of gadolinium on T1-weighted images. Computed tomographic (CT) scanning and MRI of the brain were noncontributory. Initial examination of the cerebrospinal fluid (CSF) showed lymphocytic pleocytosis with 0.011 ϫ10 9 cells/L, few atypical lymphocytes, a mildly elevated protein level (0.85 g/L), a nonreactive VDRL test, and absent oligoclonal bands. A second CSF sample had 0.006 ϫ10 9 cells/L, a protein level of 0.72 g/L, and normal results of cytologic examination. Serum and urine protein electrophoresis showed no monoclonal gammopathy or elevation of the angiotensin-converting enzyme level, and serum B 12 levels were normal. Antibodies to human immunodeficiency virus and human T-lymphotropic virus 1 (HTLV-1) were nonreactive. An antinuclear antibody ratio was mistakenly reported to be less than 1:40. A chest x-ray film was normal. A gallium body scan demonstrated increased activity in the lacrimal glands, regional lymph nodes, and right paratracheal region; chest and abdominal CT studies showed no hilar, mediastinal, or abdominal adenopathy and no evidence of sarcoidosis. The patient was discharged from the hospital and prescribed baclofen therapy.
During the next 3 months, her paraparesis progressed to near paraplegia associated with a sensory level at the umbilicus and with left arm paresthesias. On review, the first antinuclear antibody ratio was actually 1:640, and the erythrocyte sedimentation rate was 41 mm/h. Mild sicca symptoms (xerostomia and keratoconjunctivitis) were found on further questioning.
Positive findings on neurologic examination included a left afferent papillary defect, spastic paraplegia with hyperreflexia, crossed adductor responses, ankle clonus, and bilateral Babinski signs. †Data from Fox and Saita. 3 Ocular signs and ocular symptoms must both be present. Oral symptoms, histopathologic findings, and salivary gland involvement must all be present. Exclusions include preexisting lymphoma, human immunodeficiency virus infection, hepatitis virus B or C, primary fibromyalgia, and other known causes of autonomic neuropathy, keratitis sicca, or salivary gland enlargement.
‡Data from Vitali et al. 4 Exclusions include preexisting lymphoma, acquired immunodeficiency disease, sarcoidosis, graft-vs-host disease, sialadenosis, and use of antidepressant and antihypertensive drugs, neuroleptic agents, and parasympatholytic drugs.
gadolinium ( Figure, D) , at the C5-7, T3-5, and T8-11 levels and on the conus medullaris. A moderate degree of multilevel cervical spondylosis from posterior osteophytes and protruding discs near the same level of corresponding increased cervical cord signal abnormality was suggested on cervical T2-weighted images (Figure, Visual evoked potentials were prolonged in the left eye. Examination of a minor salivary gland biopsy specimen showed chronic sialadenitis, with a focus score of 3. The autoimmune serological profile and other test results are given in Table 3 . The patient was diagnosed as having CNS-SS because of the presence of sicca syndrome, abnormal serological test results, and the salivary gland biopsy results, which fulfilled the San Diego criteria 3 for "definite" SS. The patient received a pulse dose of intravenous methylprednisolone sodium succinate, 1 g/d for 3 days, followed by oral prednisone, 60 mg/d. Rheumatology consultants recommended treatment with intravenous cyclophosphamide, 0.75 g/m 2 , followed by equal monthly doses for 6 months, along with oral prednisone, 20 mg/d. With treatment, the patient experienced marked improvement in the strength of most of the muscles in her lower extremities, going from 0-1/5 to 3/5 (Medical Research Council scale). Furthermore, sensory complaints, particularly subjective paresthesias in the left upper extremity, slowly abated during the ensuing several weeks.
COMMENT
The occurrence of myelopathy in primary CNS-SS appears to be far from exceptional. In this review, 3 forms of myelopathy occurred: Brown-Séquard syndrome (1 patient), 10 18-53 years] ). All patients presented with paraparesis or paraplegia resulting from lesions at the thoracic or cervicothoracic levels. In one instance, 12 the spinal cord lesion was thoracolumbar. Our patient had multifocal MRI lesions at the C5-7, T3-5, and T8-11 levels and on the conus medullaris.
The lesion in the patient with Brown-Sé quard syndrome of abrupt onset reported by Ménage and colleagues 10 extended from C4 to the bulbomedullary junction. The patient's condition progressed during the next 3 years with partial remissions and exacerbations, and was later accompanied by optic neuropathy and white matter lesions in the centrum semiovale and cerebellum, suggestive of multiple sclerosis.
Acute transverse myelitis appears to be the most common form of spinal cord involvement in CNS-SS (10/18 patients [56%]). Symptoms develop abruptly, with se- vere neck and interscapular pain followed by sensory and motor deficits below the thoracic level of the lesion. This presentation should be distinguished from nucleus pulposus fibrocartilaginous embolism 19 and acute multiple sclerosis. 20 The acute transverse myelopathy form of CNS-SS has high mortality, probably due to vasculitis, with 1 instance of rapidly fatal spinal subarachnoid hemorrhage. 7 Nonetheless, Konttinen et al 9 successfully treated 1 patient with prednisone and plasmapheresis. More recently, Manabe et al 18 reported success with intravenous methylprednisolone followed by oral prednisone.
The subacute or chronic form of myelopathy occurred in 5 patients (28%). It usually began with unilateral sensory symptoms below the level of the lesion, sphincteral incontinence, and problems walking, eventually leading to transverse myelopathy and paraplegia. The syndrome was often accompanied by optic neuropathy and other symptoms above the level of the initial lesion in a pattern reminiscent of multiple sclerosis. 1, 5 Differential diagnosis should also include CNS lupus, spinal dural arteriovenous fistula, 21 and HTLV-1 infection. Infection with HTLV-1 produces a late-onset chronic myelopathy that predominates in women but, in contrast to the current cases, patients present with minimal sensory symptoms. 22 In addition, keratoconjunctivitis sicca is the most common form of ophthalmic involvement in HTLV-1 infection, 23 occurring in up to 48% of the patients with HTLV-1-associated tropical spastic paraparesis. In half of these patients, results of salivary gland biopsies are also consistent with SS.
The treatment currently recommended for CNS-SS is intravenous corticosteroids plus an immunosuppressive agent. Alexander 1 noted that pulse doses of intravenous corticosteroids are only effective in some patients and recommended the addition of cyclophosphamide for 12 months (initial dosage, 0.75 g/m 2 monthly, with adjustment to keep the white blood cell count at 3.0 ϫ10 9 cells/L after 7-10 days). Wright and colleagues 17 recently combined prednisone and chlorambucil, based on the significant effect of this combination on B cells.
This case review illustrates several points. First, sicca symptoms may be so subtle in SS presenting with CNS features that the diagnosis is not entertained. Second, CNS manifestations may essentially be the only extraglandular complication. Third, CNS-SS is usually multifocal, additive, and progressive, with a clinical course of fixed and cumulative deficits. When the spinal cord is involved, deficits are often acute, ie, transverse myelitis. The pathogenesis of CNS-SS appears to stem from an inflammatory ischemic vasculopathy with small vessel angiitis. 1, 6 However, the presence of antineuronal antibodies may produce paraneoplastic-type lesions. 24 In summary, the diagnosis of SS may be difficult and requires a high index of suspicion, autoimmune serological and specialized clinical testing, and minor salivary gland biopsy. Should an improper diagnosis be made, treatment with pulse doses of corticosteroids may be suboptimal. Encouraging results have been obtained with a combined therapy of corticosteroids plus cyclophosphamide or chlorambucil. 
